Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

38.77 +2.46 (+6.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
32 33 Next >
1 Beaten-Down Stock That Has a Lot to Prove in 2023
This biotech looks like a high-risk, high-reward play. 
Via The Motley Fool
3 Top Stocks to Buy If There Is a Market Pullback
All three of these stocks performed well as the market fell in 2022. 
Via The Motley Fool
Ready to Buy the Dip? Consider This Gene Editing Stock
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back. 
Via The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
5 Reasons to Buy Vertex Pharmaceuticals Now
Vertex shares are extending last year's gains, and that trend probably isn't over. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex is heading for a new phase of growth. 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in 2023
These stocks all fell by double digits last year. 
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
Is Editas Medicine Stock a Buy Now?
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist. 
Via InvestorPlace
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case? 
Via InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a 
Via Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
The gene-therapy specialist's near-term outlook is quite bullish. 
Via The Motley Fool
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
CRISPR Therapeutics Stock: Bull vs. Bear
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market? 
Via The Motley Fool
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
2 Stocks Down More Than 25% to Buy Right Now
These companies are set for a new era of growth. 
Via The Motley Fool
5 Potentially Explosive Stocks to Buy in 2023
These stocks all dropped in the double digits last year. But their future prospects are brilliant. 
Via The Motley Fool
More Likely to 5X First: CRISPR Therapeutics vs. InMode
These two companies are in very different situations but could generate significant returns for investors. 
Via The Motley Fool
2 Growth Stocks You May Regret not Buying Right Now
At their beaten-down valuations, these stocks have the potential to deliver some impressive returns. 
Via The Motley Fool
Can Cathie Wood Bounce Back in 2023?
Wood sticks by her strategy, no matter what the general market does. 
Via The Motley Fool
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023
These stocks have been solid performers despite the macroeconomic uncertainties in 2022. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS